It specifically calls for glucose monitoring in people with diabetes and renal-function monitoring when gastrointestinal reactions may cause volume depletion
However, that does not automatically make retatrutide "illegal." Instead, it currently exists in a regulatory gray area
Our data suggest that reduced capacity of GLP-1(936) to exert its glucagonostatic effect might contribute to this defect and exacerbate the hyperglycaemia caused by impaired insulin secretion
To keep that progress, she says she sometimes takes an unspecified GLP-1 medication
Important issues to review include nausea, vomiting, constipation, diarrhea, reflux, hydration status, protein intake, muscle preservation, diabetes medications, gallbladder symptoms, kidney function, history of pancreatitis, thyroid and family history considerations, and long-term maintenance strategy
Wegovy, Zepbound, and Saxenda are currently the only GLP-1 agonists approved as weight loss drugs